Latest news and press releases about Ultragenyx Pharmaceutical Inc. (RARE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases.
Price
| Price | $12.88 |
| Market Cap | $1.3B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -4.51 |
| EV / EBITDA | -5.28 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 392.35% |
| Return on Invested Capital | -53.48% |
| Return on Assets | -46.39% |
| Gross Margin | 83.12% |
| Operating Margin | -73.77% |
| Net Margin | -81.79% |
Related companies: AAPG · APGE · CELC · CGON · CNTA · DYN · IDYA
Explore sector: Healthcare · Biotechnology
More sections of RARE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks